Table 1.
Analyte | 3 hours | 6 hours | 9 hours | 12 hours |
---|---|---|---|---|
BLC | 0.23 | 1.10* | 0.86 | nd |
CD30L | 0.47 | nd | 1.71* | nd |
Eotaxin | 0.70 | 1.10* | 1.29* | nd |
Eotaxin-2 | 0.70 | 0.85 | 1.36* | 0.72 |
Fas Ligand | 0.23 | 0.55 | 0.43 | nd |
Fractalkine | 0.16 | 0.55 | 1.00 | nd |
G-CSF | 0.31 | nd | 1.20* | nd |
GM-CSF | 0.93 | 1.10* | 0.43 | 0.36 |
IFNγ | 0.47 | 1.10* | 0.64 | nd |
IL-1α | nd | 1.10* | 0.96 | 0.72 |
IL-1β | nd | nd | 0.86 | nd |
IL-2 | nd | nd | 0.86 | nd |
IL-3 | nd | 1.10* | 1.71* | nd |
IL-6 | nd | nd | 1.71* | nd |
IL-9 | nd | 0.55 | 1.71* | nd |
IL-10 | nd | nd | 1.71* | nd |
IL-12 p40/p70 | 0.35 | 0.55 | 1.03* | nd |
IL-12p70 | 0.23 | nd | 2.00* | 0.72 |
IL-13 | 0.93 | 1.10* | 2.14* | 0.72 |
IL-17 | 0.47 | 0.55 | 0.86 | nd |
I-TAC | nd | 1.10* | 1.20* | 0.72 |
KC | nd | 0.55 | 1.71* | 1.44* |
Leptin | nd | 1.10* | 1.50* | 1.44* |
LIX/CXCL5 | 0.93 | 1.65* | 0.95 | 0.72 |
Lymphotactin | nd | 0.70 | 1.19* | 0.72 |
MCP-1/CCL2 | 0.47 | 7.25* | 1.54* | nd |
M-CSF | nd | nd | 1.29 | 0.72 |
MIG | nd | 1.46* | 0.94 | nd |
MIP-1α | 0.47 | 0.37 | 1.71* | 1.44* |
MIP-1γ | 0.58 | 1.17* | 1.05* | 1.15* |
RANTES | 0.78 | 0.55 | 1.16* | 0.12 |
SDF-1 | 0.47 | nd | 0.86 | 0.36 |
TCA-3 | 0.70 | 0.55 | 0.86 | 0.72 |
TECK | nd | nd | 0.86 | nd |
TIMP-1 | 0.23 | 0.78 | 1.04* | nd |
TIMP-2 | 0.47 | nd | 1.29* | nd |
TNF-α | nd | 0.55 | 0.86 | 0.72 |
sTNFR I | 0.45 | 1.46* | 0.97 | 1.08* |
sTNFR II | nd | 0.55 | 0.86 | nd |
1Air pouches were created and 250 ng/ml IL-4 or buffer was administered into the pouch for the indicated periods of time. Pooled exudates (n ≥ 13 mice) were used to probe the membranes (Mouse inflammation antibody array I) no more than two weeks after the in vivo experiments. Results are calculated as ratios, as described in Materials and Methods. nd, not detectable; *, ratio above 1; numbers in bold characters, ratio ≥ 1.2.